Roche purchases BioImagene for approx. $100M
Under the banner of Ventana Medical Systems, Roche has purchased BioImagene, a leader in digital pathology workflow and analysis. The deal, worth approximately $100 million, helps Roche's medical device division specialize and adapt in the increasingly competitive cancer-detection industry.
"With its leadership position in pathology and its global reach, Ventana is the ideal partner for BioImagene," says Ajit Singh, CEO of BioImagene, in a statement. "Ventana is already a leader in image analysis for breast cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories worldwide. In turn, BioImagene brings to Ventana additional capabilities for scanning and analysing tissue that are not possible in the glass-slide world."
BioImagene, privately held and based in Sunnyvale, CA, creates digital images of microscopic slides and the computer software to analyse them--thereby cutting down on the time and costs associated with diagnosing cancer.
- read the Roche release
- check out the InPharm article
- here's WSJ's coverage
Related Article:
Roche pays $160M up front for diabetes tech
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: